Although 10 new opioid products with abuse-deterrent formulations (ADF) have received regulatory approval in the United States, lack of willingness by insurers to reimburse patients for their use is seen as a primary challenge limiting ADF uptake, according to the Tufts Center for the Study of Drug Development.
Related Articles
This post first appeared on Drugwonks | Welcome To The New Drugwonks.com, please read the originial post: here